+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.

Age: 18Years +All GendersPhase 3
447 locations
P

Actively Recruiting

Researchers are evaluating the combination of tucatinib with Doxil in participants who have HER2-positive locally advanced or metastatic breast cancer. This Phase 2, open-label study focuses on understanding how well this treatment works and learning about its side effects in patients who have already received at least one prior anti-HER2 therapy. Participants will receive tucatinib orally at 300 mg twice daily continuously in 28-day cycles, along with Doxil given intravenously at 40 mgm2 on the first day of each cycle. The study begins with a safety lead-in phase for the first 6 patients monitored weekly for 28 days to check tolerability. If no severe toxicities occur, enrollment will continue up to 36 participants. Throughout the study, researchers will assess tumor response using RECIST v1.1 criteria over roughly 40 months. They will also monitor side effects, progression-free survival, and other health measures. Participants will undergo regular clinical evaluations, imaging scans, and lab tests. Safety will be closely tracked during treatment and for 30 days after the last dose, with follow-up visits scheduled as needed.

Age: 18Years +All GendersPhase 2
8 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness of Rina-S, alone or combined with bevacizumab, compared to an investigators choice of platinum-based chemotherapy with or without bevacizumab. This Phase 3 study involves up to about 688 female participants worldwide with recurrent platinum-sensitive ovarian cancer who have had prior platinum-based chemotherapy. The study aims to assess how well these treatments work as second-line options. Participants will be randomly assigned to one of two groups one receiving Rina-S with or without bevacizumab every three weeks, and the other receiving investigators choice chemotherapy regimens carboplatin plus gemcitabine, paclitaxel, or pegylated liposomal doxorubicin, also with or without bevacizumab. Treatment cycles last three or four weeks depending on the medication. Participants may continue receiving treatment as long as their cancer does not worsen and they tolerate the therapy. During each treatment cycle, participants will attend one to three clinic visits for tests such as blood draws, heart activity recordings, and imaging to monitor safety and response. The main outcome measured is progression-free survival over approximately three years, with additional outcomes including overall survival and quality of life assessments up to five years. The total study duration, including screening, treatment, and follow-up, varies for each participant.

Age: 18Years +FEMALEPhase 3
12 locations
S

Actively Recruiting

Researchers are studying a new medicine called PF-08634404 combined with chemotherapy in people with advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma who have not received prior treatment for their advanced disease. This Phase 23 trial aims to evaluate the safety and effectiveness of PF-08634404 with chemotherapy compared to an approved treatment nivolumab plus chemotherapy for this type of cancer. Participants receive PF-08634404 or nivolumab intravenously along with chemotherapy in repeated treatment cycles. The study has two parts the first part focuses on assessing safety and response to the study medicine combined with chemotherapy, while the second part compares the study medicine plus chemotherapy to nivolumab plus chemotherapy to see which treatment works better. During the trial, participants undergo medical tests to monitor safety, treatment response, and cancer progression using established criteria. Researchers measure outcomes such as objective response rate, progression-free survival, overall survival, and quality of life over approximately four years. Adverse events, laboratory results, and drug concentrations are also tracked throughout treatment and for 90 days after the last intervention.

Age: 18Years +All GendersPhase 2Phase 3
102 locations